OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo, J. Souglakos, J. Engelman, M. Varella-Garcia, K. Nakagawa, P. Jänne
  • European Journal of Cancer, October 2011, Elsevier
  • DOI: 10.1016/s0959-8049(11)72627-2

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/s0959-8049(11)72627-2

The following have contributed to this page: Dr Federico Cappuzzo